REES MEDICAL SERVICES LIMITED
Company registration number 12085339 (England and Wales)
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024
PAGES FOR FILING WITH REGISTRAR
REES MEDICAL SERVICES LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
REES MEDICAL SERVICES LIMITED
BALANCE SHEET
AS AT
31 JULY 2024
31 July 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
1,135
329
Investments
4
73,386
68,420
74,521
68,749
Current assets
Debtors
5
20,347
34,509
Cash at bank and in hand
966,563
768,636
986,910
803,145
Creditors: amounts falling due within one year
6
(117,515)
(84,352)
Net current assets
869,395
718,793
Total assets less current liabilities
943,916
787,542
Provisions for liabilities
(310)
(82)
Net assets
943,606
787,460
Capital and reserves
Called up share capital
7
100
100
Profit and loss reserves
943,506
787,360
Total equity
943,606
787,460
REES MEDICAL SERVICES LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JULY 2024
31 July 2024
- 2 -

For the financial year ended 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 1 April 2025 and are signed on its behalf by:
Mr R J Rees
Director
Company registration number 12085339 (England and Wales)
REES MEDICAL SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024
- 3 -
1
Accounting policies
Company information

Rees Medical Services Limited is a private company limited by shares incorporated in England and Wales. The registered office is Dyke Yaxley Limited, 1 Brassey Road, Old Potts Way, Shrewsbury, Shropshire, SY3 7FA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
33% Straight Line
Fixtures and fittings
25% Straight Line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Transaction costs are expensed to profit or loss as incurred. Changes in fair value are recognised in other comprehensive income except to the extent that a gain reverses a loss previously recognised in profit or loss, or a loss exceeds the accumulated gains recognised in equity; such gains and loss are recognised in profit or loss.

REES MEDICAL SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2024
1
Accounting policies
(Continued)
- 4 -
1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

REES MEDICAL SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2024
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
3
3
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2023
6,933
Additions
1,628
At 31 July 2024
8,561
Depreciation and impairment
At 1 August 2023
6,604
Depreciation charged in the year
822
At 31 July 2024
7,426
Carrying amount
At 31 July 2024
1,135
At 31 July 2023
329
4
Fixed asset investments
2024
2023
£
£
Other investments other than loans
73,386
68,420
REES MEDICAL SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2024
4
Fixed asset investments
(Continued)
- 6 -
Movements in fixed asset investments
Investments
£
Cost or valuation
At 1 August 2023
68,420
Additions
519
Valuation changes
4,897
Disposals
(450)
At 31 July 2024
73,386
Carrying amount
At 31 July 2024
73,386
At 31 July 2023
68,420
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
20,272
34,509
Other debtors
75
-
0
20,347
34,509
6
Creditors: amounts falling due within one year
2024
2023
£
£
Taxation and social security
110,511
77,049
Other creditors
7,004
7,303
117,515
84,352
REES MEDICAL SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2024
- 7 -
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Authorised
Ordinary A Shares of £1 each
80
80
80
80
Ordinary B Shares of £1 each
20
20
20
20
100
100
100
100
Issued and fully paid
Ordinary A Shares of £1 each
80
80
80
80
Ordinary B Shares of £1 each
20
20
20
20
100
100
100
100

Each class of Ordinary Share carries full voting, dividend and capital distribution (including on winding up) rights.

2024-07-312023-08-01falsefalsefalse01 April 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMrs J E ReesMr R J Rees120853392023-08-012024-07-31120853392024-07-31120853392023-07-3112085339core:OtherPropertyPlantEquipment2024-07-3112085339core:OtherPropertyPlantEquipment2023-07-3112085339core:CurrentFinancialInstrumentscore:WithinOneYear2024-07-3112085339core:CurrentFinancialInstrumentscore:WithinOneYear2023-07-3112085339core:CurrentFinancialInstruments2024-07-3112085339core:CurrentFinancialInstruments2023-07-3112085339core:ShareCapital2024-07-3112085339core:ShareCapital2023-07-3112085339core:RetainedEarningsAccumulatedLosses2024-07-3112085339core:RetainedEarningsAccumulatedLosses2023-07-3112085339core:ShareCapitalOrdinaryShares2024-07-3112085339core:ShareCapitalOrdinaryShares2023-07-3112085339bus:Director22023-08-012024-07-3112085339core:PlantMachinery2023-08-012024-07-3112085339core:FurnitureFittings2023-08-012024-07-31120853392022-08-012023-07-3112085339core:OtherPropertyPlantEquipment2023-07-3112085339core:OtherPropertyPlantEquipment2023-08-012024-07-3112085339core:WithinOneYear2024-07-3112085339core:WithinOneYear2023-07-3112085339bus:PrivateLimitedCompanyLtd2023-08-012024-07-3112085339bus:SmallCompaniesRegimeForAccounts2023-08-012024-07-3112085339bus:FRS1022023-08-012024-07-3112085339bus:AuditExemptWithAccountantsReport2023-08-012024-07-3112085339bus:Director12023-08-012024-07-3112085339bus:FullAccounts2023-08-012024-07-31xbrli:purexbrli:sharesiso4217:GBP